8-KMaterial AgreementsOther EventsExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Material Agreement (Dec 19, 2013)

Filed December 19, 2013For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) has announced a significant divestiture of its diabetes business to AstraZeneca AB for a substantial sum. This strategic move involves selling key diabetes assets, including prominent drugs like Onglyza, Kombiglyze, dapagliflozin, Byetta, Bydureon, Metreleptin, and Symlin. The deal includes an upfront payment of $2.7 billion from AstraZeneca, with potential for additional milestone and royalty payments up to $1.4 billion plus royalties through 2025. This transaction allows BMY to streamline its focus and allocate resources to other therapeutic areas. The sale also encompasses manufacturing facilities, including the former Amylin Pharmaceuticals plant in West Chester, Ohio, and the future sale of the Mt. Vernon, Indiana facility. The agreement imposes certain business conduct restrictions on BMY for the diabetes business and prohibits BMY from commercializing competing products for five years post-closing, with specific exceptions. This strategic realignment is expected to close in the first quarter of 2014, pending regulatory approvals.

Key Highlights

  • 1BMY is selling its entire diabetes business to AstraZeneca for a significant financial package.
  • 2The deal includes an upfront payment of $2.7 billion, with potential milestone and royalty payments totaling up to $1.4 billion.
  • 3Key diabetes products included in the sale are Onglyza, Kombiglyze, dapagliflozin, Byetta, Bydureon, Metreleptin, and Symlin.
  • 4The transaction includes the sale of manufacturing facilities in West Chester, Ohio, and the planned sale of the Mt. Vernon, Indiana facility.
  • 5BMY will be restricted from competing in the diabetes market for five years post-closing, with certain exceptions.
  • 6The sale is expected to close in Q1 2014, subject to regulatory approvals.
  • 7BMY also provided 2014 non-GAAP earnings per share guidance and will hold an investor conference call to discuss the transaction.

Frequently Asked Questions

While not explicitly stated as the sole reason, this divestiture is a strategic move allowing Bristol-Myers Squibb to focus its resources and efforts on other therapeutic areas where it sees greater growth potential and strategic alignment, rather than managing a diverse portfolio that includes its diabetes assets.

Bristol-Myers Squibb is set to receive an upfront payment of $2.7 billion from AstraZeneca. Additionally, there are potential milestone payments of up to $1.4 billion, contingent on regulatory and sales achievements, as well as ongoing royalty payments based on net sales through 2025. There may also be further payments if certain assets are transferred later.

By divesting its diabetes business, BMY is streamlining its operations and likely reallocating capital and R&D towards its core therapeutic areas. However, the agreement includes a five-year restriction on BMY from commercializing competing diabetes products, limiting its immediate ability to re-enter this market.

The transaction is anticipated to close in the first quarter of 2014, provided that all customary regulatory approvals (including in the U.S., Germany, and Austria) and other closing conditions are met.